AC Immune SA announced its participation in the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025), scheduled for April 1-5, 2025, in Vienna, Austria. The company will host an industry symposium on April 2, 2025, focusing on active immunotherapies for neurodegenerative diseases.
The symposium, titled 'Unlocking active immunotherapy for tailored prevention strategies in neurodegenerative diseases,' will feature key opinion leaders and AC Immune leadership. Presentations will cover significant pipeline assets, including ACI-7104.056 in the Phase 2 VacSYn trial, ACI-35.030/JNJ2056 in the Phase 2b Re t ain study, and ACI-24.060 in the Phase 1b/2 ABATE study.
Additionally, AC Immune will provide updates on its Morphomer small molecules targeting Tau and alpha-synuclein, as well as its Morphomer-antibody drug conjugates. These presentations highlight the company's ongoing progress and strategic focus on precision therapeutics for neurodegenerative conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.